RxDoctor Payments Data

Christina Tang, DO

Infectious Disease · Indianapolis, INNPI 1689899700

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 29.9% of the total. Reporting peaked in 2019 at $712 and has fallen 80.3% since, to $140 in 2025.

$1,085in general payments, 2019–2025

Across 68 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$324
  • Merck$227
  • Johnson & Johnson$185
  • Viiv Healthcare Company$115
  • Gilead$110
  • Theratechnologies Inc.$75
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$1,085100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,085 in reported general payments places this provider in the 65th percentile of 152 infectious disease providers in Indiana.

See all infectious disease providers in Indiana

Medicare billing

Part B allowed, 2024
$25,366
Medicare patients
111
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala143$644,361
GenvoyaElviteg/Cob/Emtri/Tenof Alafen49$207,861
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf25$125,668
OdefseyEmtricitab/Rilpiviri/Tenof Ala23$99,140
TivicayDolutegravir Sodium36$92,576
TriumeqAbacavir/Dolutegravir/Lamivudi24$88,303
PrezcobixDarunavir/Cobicistat35$83,663
JulucaDolutegravir/Rilpivirine24$82,608
DescovyEmtricitabine/Tenofov Alafenam17$56,151
Darunavir23$36,445
PifeltroDoravirine12$20,054
Cefazolin Sodium18$1,412
Abacavir-LamivudineAbacavir Sulfate/Lamivudine20$1,377
ValacyclovirValacyclovir Hcl28$876
Doxycycline Hyclate22$507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$110$908,373209 claims
Viiv Healthcare CompanyTivicay, Triumeq, Juluca$115$263,48784 claims
Johnson & JohnsonPrezcobix$185$83,66335 claims
MerckPifeltro$227$20,05412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 152 infectious disease providers in Indiana.

Other infectious disease in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →